ClinicalTrials.gg
CompletedNCT05283395Updated Apr 3, 2024Results posted

Rocklatan® Evaluation

A Phase 4 interventional study of Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution in Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-03.

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
136
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing netarsudil in Glaucoma — 2 open to participants now, 2 under way, none of them phase 3. netarsudil · Glaucoma.

Enrollment
6th of 11
136 · median 136
Started
2022
the only one that year
Phase 4
4 of 11
2 open now
Registered
7th of 11
by date
Lead sponsor
6 of 11
Aerie Pharmaceuticals

Among the 11 studies testing netarsudil in Glaucoma, this one is the 6th largest by enrollment, is the only one that started in 2022, is one of 4 in phase 4, and was the 7th registered.

Glaucoma

1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.

Browse Glaucoma studies →

Open to participants now

2 of the 11 studies testing netarsudil in Glaucoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing netarsudil in Glaucoma, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the IOP-lowering effect when subjects are switched from various latanoprost-based regimens to Rocklatan. Subjects will stop their IOP-lowering medical therapy regimen and dose with Rocklatan for the duration of the study (12 weeks).

Read the detailed description

Enrollment will be stratified according to subject's IOP-lowering medical therapy regimen as follows:

  • Latanoprost monotherapy (Latanoprost Mono)
  • Latanoprost plus 1 additional IOP-lowering agent (Latanoprost +1)
  • Latanoprost plus 2 additional IOP-lowering agents (Latanoprost +2)

Aerie Pharmaceuticals was acquired by Alcon Research LLC on November 22, 2022.

03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • Glaucoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female subjects age 18 or older
  • Current diagnosis of open-angle glaucoma or ocular hypertension
  • Subject currently being treated with latanoprost alone or latanoprost plus 1 or 2 additional agents/bottles. Current IOP lowering regimen is stable for at least 30 days prior to Baseline Visit
  • Treated IOP ≥ 20 mmHg measured in the morning (before noon) at the Baseline Visit by Goldmann applanation tonometer
  • Best corrected Snellen visual acuity of 20/100 or better in both eyes
  • Willingness to follow protocol requirements, including signed and health information release forms, routine follow-up schedule, completing questionnaires

Key Exclusion Criteria:

  • Have any active ocular disease other than open-angle glaucoma or ocular hypertension that would interfere with study interpretation
  • Use of fixed dose combination agents as part of the patient's Baseline IOP lowering therapy regimen, if not also on latanoprost
  • Active ocular infection/inflammation or history of uveitis
  • Aphakic or pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema
  • Any systemic disease or clinical evidence of any condition which would make the subject, in the opinion of the investigator, unsuitable for the study or could potentially confound the study results
  • Use of topical, periorbital, intravitreal or systemic within previous 3 months or expected use during the course of the study
  • Prior participation in any drug or device study within the last 30 days prior to the Baseline Visit.
  • Known sensitivity or allergy to the study medication or components
  • Females who are pregnant, nursing, or planning a pregnancy during the study
  • Positive pregnancy test at Baseline Visit (women of only)
  • Women of childbearing potential who are not using a medically acceptable form of
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Rocklatan

    Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution, one drop in each eye in the evening for 12 weeks

    Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution

Interventions

  • DrugNetarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution

    Drug page: Netarsudil

    Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension

    Also known as: Rocklatan®

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12

    IOP was measured using Goldmann applanation tonometry at the Baseline and Week 12 visits. One eye (study eye) contributed data to this analysis. A negative value indicates an improvement in IOP. No hypothesis testing was prespecified for this endpoint.

    Time frame: Baseline (Day 0 pretreatment), Week 12

07

Results

Posted Apr 3, 2024

Participant flow

Participants were recruited from 21 investigative sites located in the United States.

Participant flow — Overall Study
MilestoneRocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)
Started614530
Completed543725
Not completed785
Withdrew: Adverse event440
Withdrew: Patient lost to follow-up001
Withdrew: Patient withdrawal242
Withdrew: Investigator decision101
Withdrew: Enrolled in error001

Outcome measures

PrimaryMean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12

IOP was measured using Goldmann applanation tonometry at the Baseline and Week 12 visits. One eye (study eye) contributed data to this analysis. A negative value indicates an improvement in IOP. No hypothesis testing was prespecified for this endpoint.

Time frame:
Baseline (Day 0 pretreatment), Week 12
Reported as:
Mean · percent change
Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12
percent changeRocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)Rocklatan Total
Mean Percent Change From Baseline in Intraocular Pressure (IOP) at Week 12-21.2 ± 17.46-15.7 ± 21.91-16.9 ± 17.31-18.5 ± 18.96

Adverse events

Collected over Adverse events (AEs) were collected for the duration of individual participation in the study, approximately 12 weeks (±7 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rocklatan (Latanoprost Mono)0/61 (0%)0/61 (0%)9/61 (14.8%)
Rocklatan (Latanoprost +1)0/45 (0%)0/45 (0%)10/45 (22.2%)
Rocklatan (Latanoprost +2)0/30 (0%)1/30 (3.3%)6/30 (20%)
Most frequent serious events
Most frequent serious events
EventRocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)
Femur fractureInjury, poisoning and procedural complications0/610/451/30
Most frequent other events
Most frequent other events
EventRocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)
Conjunctival hyperaemiaEye disorders9/6110/456/30

Baseline characteristics

Safety Population: All subjects who have received at least 1 dose of study medication

Age, Continuous
Age, Continuous(years)Rocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)Total
Mean67.4 ± 11.271.1 ± 10.0669.3 ± 11.6069.0 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)Rocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)Total
Female32231469
Male29221667
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)Total
Hispanic or Latino1371030
Not Hispanic or Latino483820106
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Rocklatan (Latanoprost Mono)Rocklatan (Latanoprost +1)Rocklatan (Latanoprost +2)Total
American Indian or Alaska Native0224
Asian1214
Black or African American1391133
White46321694
Other1001
08

Study locations

21 sites
  • North Valley Eye Medical Group
    Mission Hills, California 91345, United States
  • Visionary Eye Institute
    Newport Beach, California 92663, United States
  • California Eye Specialists Medical Group
    Pasadena, California 91107, United States
  • North Bay Eye Associates
    Petaluma, California 94954, United States
  • Shettle Eye Research
    Largo, Florida 33773, United States
  • Center For Sight
    Venice, Florida 34285, United States
  • Georgia Eye Partners
    Atlanta, Georgia 30342, United States
  • Coastal Research Associates LLC
    Roswell, Georgia 30076, United States
  • Tekwani Vision Center
    Saint Louis, Missouri 63128, United States
  • OCLI Vision
    Manhasset, New York 11030, United States
  • Mark J. Weiss, MD, Inc.
    Tulsa, Oklahoma 74104, United States
  • Scott & Christie and Associates, PC
    Cranberry Township, Pennsylvania 16066, United States
  • Advancing Vision Research
    Goodlettsville, Tennessee 37072, United States
  • VRF Eye Specialty Group
    Memphis, Tennessee 38120, United States
  • Total Eye Care, PA
    Memphis, Tennessee 38199, United States
  • Keystone Research
    Austin, Texas 78731, United States
  • Louis M. Alpern, M.D., M.P.H., P.A
    El Paso, Texas 79902, United States
  • Houston Eye Associates
    Houston, Texas 77025, United States
  • Emerson Clinical Research Institute
    Falls Church, Virginia 22046, United States
  • Vistar Eye Center
    Roanoke, Virginia 24016, United States
  • The Eye Centers of Racine and Kenosha
    Racine, Wisconsin 53405, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Mar 2023, 11 months.

Results were first posted in Apr 2024, 1 year after primary completion.

Of 44 phase 4 interventional studies under Glaucoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 66. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 7, 2022
First posted
Mar 17, 2022
StartActual
Mar 28, 2022
Primary completionActual
Mar 22, 2023
CompletionActual
Mar 22, 2023
Results first posted
Apr 3, 2024
Last update
Apr 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05283395
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Mar 28, 2022
Primary completion
Mar 22, 2023
Completion
Mar 22, 2023
Results posted
Apr 3, 2024
Last update
Apr 3, 2024

Study contacts

Scientific Advisor, Clinical R&D
study director · Alcon Research, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion